Dedicated to discovering, developing, and commercializing novel therapeutics to transform the treatment of patients with grievous blood-based disorders
GBT (NASDAQ: GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.
Year Invested: 2012
Location: South San Francisco, Calif.